IGHE and asthma: In a retrospective study (n = 52; 26 in each group), patients with asthma with mean IgE 221 IU/mL (Group 1) received omalizumab at a mean dose of 426 mg/month (range: 150–900 mg/month), whereas patients with mean IgE 2371 IU/mL (Group 2) received a mean dose of 886 mg/month (range: 400–1200 mg/month) for 6 months or longer duration.